RNS Number : 8321X
Shield Therapeutics PLC
01 September 2022

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Launch of new corporate brand and website to support strategic vision and accelerated growth ambitions

Company unveils a new visual identity, website, and commitment to innovation

London, UK, 1 September 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces the launch of its new corporate brand and website.

The new corporate brand and website aligns with the Company's future vision and presents the significant transformation the Group has undergone, following new leadership and the successful launch of Accrufer® in the US. The new brand identity embodies the renewed sense of purpose, energy and enthusiasm of all its employees with a bright, progressive and dynamic feel representing a company that has transformed itself and is on a growth trajectory. Additionally, the new website provides key stakeholders, partners, and investors with a more modern and cleaner look and feel, making it easier to navigate and locate all up to date information and resources.

Greg Madison, Chief Executive Officer of Shield Therapeutics, said: *"The launch of our new corporate brand and website is timely as we continue to make excellent progress by the 'new' Shield ethos and are pleased to offer our key stakeholders an updated website in order to learn more about our business, strategy and geographical markets that we are operating in. This is another step forward to help achieve our mission 'to improve lives together' and make Accrufer® the treatment of choice to treat iron deficiency."*

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	+44 (0) 191 511 8500
Hans-Peter Rudolf, CFO	
Nominated Adviser and Joint Broker	
Peel Hunt LLP	
James Steel/Christopher Golden	+44 (0)20 7418 8900
Joint Broker	
finnCap Ltd	
Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks	+44 (0)20 7220 0500
Financial PR & IR Advisor	
Walbrook PR	
Lianne Applegarth/Alice Woodings	+44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)	
LifeSci Advisors, LLC	
John Mullaly	+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUAONRURUWOAR